Get the Stockscreener App
8.38
3.68%
-0.32
After Hours:
8.37
-0.01
-0.12%
Fibrogen Inc stock is traded at $8.38, with a volume of 11,659.
It is down -3.68% in the last 24 hours and down -8.21% over the past month.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
See More
Previous Close:
$8.70
Open:
$8.71
24h Volume:
11,659
Relative Volume:
0.40
Market Cap:
$33.90M
Revenue:
$147.75M
Net Income/Loss:
$-284.23M
P/E Ratio:
-2.8601
EPS:
-2.93
Net Cash Flow:
$-317.54M
1W Performance:
-0.48%
1M Performance:
-8.21%
6M Performance:
+8.65%
1Y Performance:
-2.02%
1-Day Range:
$8.37
$8.795
1-Week Range:
$8.30
$9.0883
52-Week Range:
$4.85
$21.94
Fibrogen Inc Stock (FGEN) Company Profile
Name
Fibrogen Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO, CA
Compare FGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
8.38 | 35.20M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
| May-01-20 | Initiated | Cowen | Market Perform |
| Apr-27-20 | Initiated | BofA/Merrill | Neutral |
| May-29-19 | Resumed | Goldman | Neutral |
| May-10-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-19 | Initiated | Piper Jaffray | Neutral |
| Feb-11-19 | Resumed | Stifel | Buy |
| Dec-19-18 | Upgrade | Citigroup | Neutral → Buy |
| Aug-08-17 | Reiterated | Leerink Partners | Outperform |
| Aug-08-17 | Reiterated | Stifel | Buy |
| Jul-21-17 | Downgrade | Goldman | Buy → Neutral |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Feb-11-16 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
| Dec-04-15 | Initiated | Citigroup | Buy |
| Sep-23-15 | Initiated | Lake Street | Hold |
| Jul-29-15 | Initiated | Citigroup | Buy |
| Jul-20-15 | Upgrade | Goldman | Neutral → Buy |
| Dec-09-14 | Initiated | Stifel | Buy |
View All
Fibrogen Inc Stock (FGEN) Latest News
FibroGen Investor Suit Dismissed Following $28.5 Million Deal - Bloomberg Law News
Can FibroGen Inc. (1FG0) stock deliver strong annual returnsSell Signal & AI Powered Market Entry Strategies - Newser
Will FibroGen Inc. (1FG0) stock outperform global peers2025 Valuation Update & Safe Capital Growth Stock Tips - Newser
FibroGen (FGEN) Stock Analysis Report | Financials & Insights - Benzinga
Is FibroGen Inc. (1FG0) stock overpriced at current multiplesDividend Hike & Weekly Momentum Picks - Newser
How FibroGen Inc. (1FG0) stock reacts to fiscal policiesWeekly Trade Review & Weekly Watchlist for Hot Stocks - Newser
How dovish Fed policy supports FibroGen Inc. (1FG0) stockAnalyst Downgrade & Entry and Exit Point Strategies - Newser
How supply shortages influence FibroGen Inc. (1FG0) stockSell Signal & Weekly Return Optimization Alerts - Newser
Is FibroGen Inc. (1FG0) stock a top hedge fund pick2025 Fundamental Recap & Smart Allocation Stock Tips - Newser
FibroGen, Inc. to Present at Oppenheimer Movers in Rare Disease Summit on December 11, 2025 - Quiver Quantitative
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit - GlobeNewswire
FibroGen (NASDAQ: FGEN) to present at Oppenheimer Movers in Rare Disease Summit Dec. 11 - Stock Titan
Will FibroGen Inc. stock outperform international peers2025 Fundamental Recap & AI Powered Buy and Sell Recommendations - moha.gov.vn
Why FibroGen Inc. (1FG0) stock is trending on social mediaJuly 2025 PreEarnings & AI Enhanced Execution Alerts - moha.gov.vn
FibroGen started at buy by H.C. Wainwright - MSN
What valuation multiples suggest for FibroGen Inc. stockWeekly Trade Analysis & Verified Momentum Watchlists - newser.com
Can FibroGen Inc. (1FG0) stock ride next bull market cycle2025 Pullback Review & Short-Term Trading Opportunity Alerts - newser.com
Why FibroGen Inc. stock remains resilientPortfolio Return Summary & Real-Time Buy Signal Alerts - newser.com
Can FibroGen Inc. (1FG0) stock deliver consistent EPS growthJuly 2025 Decliners & Weekly Top Gainers Alerts - newser.com
Is FibroGen Inc. stock vulnerable to regulatory risks2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - newser.com
Can FibroGen Inc. (1FG0) stock resist broad market declines2025 Volatility Report & Intraday High Probability Alerts - newser.com
Will earnings trigger a reversal in FibroGen Inc.Trade Volume Summary & Reliable Volume Spike Trade Alerts - newser.com
What drives FibroGen Inc stock priceCandlestick Trading Patterns & Free Take Advantage Of Momentum - earlytimes.in
Chart based exit strategy for FibroGen Inc.July 2025 Summary & Daily Technical Forecast Reports - newser.com
What hedge fund activity signals for FibroGen Inc. stockWeekly Trading Summary & Daily Growth Stock Investment Tips - newser.com
Fibrogen CEO Wettig Thane buys shares worth $33,749 By Investing.com - Investing.com Australia
Fibrogen Inc Stock (FGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):